| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myeloproliferative Disorders | 6 | 2021 | 882 | 1.500 |
Why?
|
| Isochromosomes | 2 | 2021 | 55 | 1.150 |
Why?
|
| Emulsions | 2 | 2016 | 86 | 1.030 |
Why?
|
| Myelodysplastic Syndromes | 5 | 2021 | 3155 | 0.890 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 2 | 2021 | 121 | 0.850 |
Why?
|
| Polymerase Chain Reaction | 5 | 2016 | 3464 | 0.770 |
Why?
|
| Pathologists | 1 | 2021 | 101 | 0.710 |
Why?
|
| Biological Products | 1 | 2021 | 318 | 0.590 |
Why?
|
| Blood Platelet Disorders | 1 | 2017 | 35 | 0.570 |
Why?
|
| Loss of Heterozygosity | 1 | 2018 | 623 | 0.550 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2017 | 214 | 0.520 |
Why?
|
| Lymphoma, B-Cell | 4 | 2014 | 930 | 0.460 |
Why?
|
| Bone Marrow | 3 | 2021 | 2440 | 0.460 |
Why?
|
| DNA Mutational Analysis | 5 | 2017 | 2356 | 0.440 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2013 | 64 | 0.420 |
Why?
|
| Cytochrome P-450 CYP2E1 | 1 | 2012 | 18 | 0.420 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2012 | 59 | 0.400 |
Why?
|
| High-Throughput Nucleotide Sequencing | 4 | 2014 | 2363 | 0.400 |
Why?
|
| Genes, bcl-2 | 1 | 2012 | 172 | 0.400 |
Why?
|
| Germ-Line Mutation | 1 | 2017 | 1101 | 0.390 |
Why?
|
| Aurora Kinase A | 1 | 2013 | 209 | 0.390 |
Why?
|
| DNA Copy Number Variations | 1 | 2018 | 1576 | 0.380 |
Why?
|
| Neoplasms, Second Primary | 3 | 2015 | 1388 | 0.360 |
Why?
|
| Genes, myc | 1 | 2012 | 372 | 0.360 |
Why?
|
| Karyotyping | 5 | 2017 | 1064 | 0.350 |
Why?
|
| Hematologic Neoplasms | 2 | 2021 | 1956 | 0.350 |
Why?
|
| Lymphoma, T-Cell | 1 | 2013 | 367 | 0.340 |
Why?
|
| Chromosome Deletion | 2 | 2013 | 1057 | 0.320 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2021 | 3656 | 0.320 |
Why?
|
| Immunophenotyping | 6 | 2017 | 1723 | 0.320 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2011 | 675 | 0.310 |
Why?
|
| Leukemia, Myeloid, Acute | 5 | 2016 | 7273 | 0.280 |
Why?
|
| Genes, p53 | 1 | 2011 | 1140 | 0.280 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2012 | 796 | 0.280 |
Why?
|
| Flavoproteins | 1 | 2006 | 31 | 0.260 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2012 | 2454 | 0.260 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2016 | 1145 | 0.260 |
Why?
|
| DNA | 1 | 2013 | 3041 | 0.240 |
Why?
|
| Leukemia, B-Cell | 2 | 2014 | 115 | 0.220 |
Why?
|
| Circadian Rhythm | 1 | 2006 | 331 | 0.220 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2006 | 626 | 0.200 |
Why?
|
| Transcriptional Activation | 1 | 2006 | 1107 | 0.190 |
Why?
|
| Mutation | 7 | 2021 | 15917 | 0.190 |
Why?
|
| Humans | 31 | 2021 | 270713 | 0.180 |
Why?
|
| Lymphoma, Large-Cell, Anaplastic | 2 | 2014 | 389 | 0.170 |
Why?
|
| Immunohistochemistry | 5 | 2013 | 7648 | 0.170 |
Why?
|
| Trans-Activators | 1 | 2006 | 1626 | 0.170 |
Why?
|
| Breast Implants | 2 | 2014 | 375 | 0.170 |
Why?
|
| Germ Cells | 1 | 2021 | 329 | 0.160 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2013 | 1195 | 0.160 |
Why?
|
| Antigens, CD | 2 | 2014 | 1420 | 0.150 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2015 | 3582 | 0.150 |
Why?
|
| Models, Molecular | 1 | 2021 | 1736 | 0.130 |
Why?
|
| Microfluidics | 1 | 2016 | 32 | 0.130 |
Why?
|
| Clonal Evolution | 1 | 2017 | 250 | 0.120 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2013 | 843 | 0.120 |
Why?
|
| Calreticulin | 1 | 2015 | 84 | 0.120 |
Why?
|
| Gene Expression Regulation | 1 | 2006 | 4105 | 0.120 |
Why?
|
| Cytogenetic Analysis | 2 | 2014 | 574 | 0.120 |
Why?
|
| Disease Susceptibility | 1 | 2017 | 546 | 0.120 |
Why?
|
| RNA, Messenger | 2 | 2016 | 6344 | 0.120 |
Why?
|
| CD5 Antigens | 1 | 2014 | 129 | 0.110 |
Why?
|
| Prognosis | 5 | 2021 | 22528 | 0.110 |
Why?
|
| Poly(A)-Binding Proteins | 1 | 2013 | 33 | 0.110 |
Why?
|
| RNA, Neoplasm | 1 | 2016 | 805 | 0.110 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2015 | 2312 | 0.110 |
Why?
|
| Family | 1 | 2017 | 782 | 0.110 |
Why?
|
| Pedigree | 1 | 2017 | 2040 | 0.110 |
Why?
|
| Neoplasms | 3 | 2014 | 15949 | 0.110 |
Why?
|
| Myelodysplastic-Myeloproliferative Diseases | 1 | 2014 | 120 | 0.110 |
Why?
|
| Adult | 10 | 2021 | 82041 | 0.100 |
Why?
|
| Composite Lymphoma | 1 | 2012 | 18 | 0.100 |
Why?
|
| Gene Expression Regulation, Leukemic | 1 | 2016 | 586 | 0.100 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 2 | 2014 | 331 | 0.100 |
Why?
|
| Benzene | 1 | 2012 | 47 | 0.100 |
Why?
|
| Xenobiotics | 1 | 2012 | 40 | 0.100 |
Why?
|
| Leukemia, Prolymphocytic, B-Cell | 1 | 2012 | 7 | 0.100 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 2016 | 456 | 0.100 |
Why?
|
| Iatrogenic Disease | 1 | 2013 | 194 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2021 | 4965 | 0.100 |
Why?
|
| Cytochrome P-450 CYP1A2 | 1 | 2012 | 66 | 0.100 |
Why?
|
| K562 Cells | 1 | 2012 | 344 | 0.100 |
Why?
|
| Gene Rearrangement | 2 | 2013 | 809 | 0.100 |
Why?
|
| Splenic Neoplasms | 1 | 2012 | 124 | 0.090 |
Why?
|
| Aged | 10 | 2015 | 73613 | 0.090 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2013 | 194 | 0.090 |
Why?
|
| Thiazoles | 1 | 2015 | 727 | 0.090 |
Why?
|
| Neoplasm Grading | 2 | 2013 | 1828 | 0.090 |
Why?
|
| Female | 14 | 2017 | 148885 | 0.090 |
Why?
|
| Male | 11 | 2017 | 128479 | 0.090 |
Why?
|
| Lymphoma, Mantle-Cell | 2 | 2014 | 750 | 0.090 |
Why?
|
| Middle Aged | 10 | 2016 | 90533 | 0.090 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2013 | 690 | 0.090 |
Why?
|
| Oncogenes | 1 | 2013 | 697 | 0.090 |
Why?
|
| Autoimmune Diseases | 1 | 2013 | 435 | 0.080 |
Why?
|
| Biopsy | 1 | 2017 | 3490 | 0.080 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2021 | 5777 | 0.080 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 15275 | 0.080 |
Why?
|
| Immunocompromised Host | 1 | 2013 | 718 | 0.080 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2013 | 1044 | 0.070 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2021 | 2903 | 0.070 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 2478 | 0.070 |
Why?
|
| Aged, 80 and over | 5 | 2014 | 31116 | 0.070 |
Why?
|
| Blotting, Western | 1 | 2013 | 3568 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2013 | 1544 | 0.070 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 1436 | 0.070 |
Why?
|
| Case-Control Studies | 2 | 2014 | 6233 | 0.070 |
Why?
|
| Diagnostic Imaging | 1 | 2014 | 1174 | 0.070 |
Why?
|
| Cryptochromes | 1 | 2006 | 14 | 0.070 |
Why?
|
| Period Circadian Proteins | 1 | 2006 | 42 | 0.070 |
Why?
|
| CLOCK Proteins | 1 | 2006 | 33 | 0.070 |
Why?
|
| ARNTL Transcription Factors | 1 | 2006 | 51 | 0.070 |
Why?
|
| Crosses, Genetic | 1 | 2006 | 251 | 0.060 |
Why?
|
| Disease Progression | 1 | 2017 | 6881 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2006 | 98 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2013 | 1656 | 0.060 |
Why?
|
| Retrospective Studies | 2 | 2021 | 39959 | 0.060 |
Why?
|
| Diagnosis, Differential | 4 | 2016 | 4838 | 0.060 |
Why?
|
| Hodgkin Disease | 1 | 2013 | 1485 | 0.060 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2016 | 2636 | 0.060 |
Why?
|
| Genes, Reporter | 1 | 2006 | 813 | 0.060 |
Why?
|
| Multiprotein Complexes | 1 | 2006 | 380 | 0.060 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2014 | 2488 | 0.050 |
Why?
|
| Flow Cytometry | 3 | 2014 | 3040 | 0.050 |
Why?
|
| Biomarkers, Tumor | 4 | 2014 | 10726 | 0.050 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 7055 | 0.050 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6257 | 0.050 |
Why?
|
| Stress, Physiological | 1 | 2006 | 489 | 0.050 |
Why?
|
| Pyrimidines | 1 | 2015 | 3671 | 0.050 |
Why?
|
| Models, Genetic | 1 | 2006 | 1161 | 0.050 |
Why?
|
| Neoplasm Proteins | 1 | 2013 | 3345 | 0.050 |
Why?
|
| Disease-Free Survival | 3 | 2021 | 10268 | 0.050 |
Why?
|
| Sensitivity and Specificity | 3 | 2014 | 5157 | 0.050 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 1624 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2013 | 9463 | 0.040 |
Why?
|
| Breast Neoplasms | 2 | 2014 | 16244 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 3205 | 0.040 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 14878 | 0.040 |
Why?
|
| Cell Cycle Proteins | 1 | 2006 | 2112 | 0.040 |
Why?
|
| Philadelphia Chromosome | 1 | 2021 | 852 | 0.030 |
Why?
|
| Skin Neoplasms | 1 | 2013 | 4899 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2006 | 5692 | 0.030 |
Why?
|
| Disseminated Intravascular Coagulation | 1 | 2016 | 98 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2006 | 7052 | 0.030 |
Why?
|
| Nuclear Proteins | 1 | 2006 | 3435 | 0.030 |
Why?
|
| Semiconductors | 1 | 2014 | 20 | 0.030 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2014 | 36 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 16741 | 0.030 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 5145 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 818 | 0.030 |
Why?
|
| Lewis X Antigen | 1 | 2013 | 38 | 0.030 |
Why?
|
| Reed-Sternberg Cells | 1 | 2013 | 46 | 0.030 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2014 | 206 | 0.030 |
Why?
|
| Leukocytosis | 1 | 2014 | 122 | 0.030 |
Why?
|
| Young Adult | 1 | 2012 | 22243 | 0.030 |
Why?
|
| T-Cell Intracellular Antigen-1 | 1 | 2013 | 17 | 0.030 |
Why?
|
| Fucosyltransferases | 1 | 2013 | 78 | 0.030 |
Why?
|
| Leukemia, Hairy Cell | 1 | 2014 | 129 | 0.030 |
Why?
|
| Histiocytes | 1 | 2013 | 94 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 6193 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2013 | 205 | 0.030 |
Why?
|
| Antigens, CD20 | 1 | 2013 | 207 | 0.030 |
Why?
|
| Gene Rearrangement, B-Lymphocyte | 1 | 2012 | 47 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2014 | 316 | 0.030 |
Why?
|
| Genes, Neoplasm | 1 | 2014 | 314 | 0.030 |
Why?
|
| Mutagenesis, Insertional | 1 | 2013 | 216 | 0.030 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2012 | 243 | 0.020 |
Why?
|
| Adolescent | 1 | 2012 | 32689 | 0.020 |
Why?
|
| Watchful Waiting | 1 | 2013 | 293 | 0.020 |
Why?
|
| Device Removal | 1 | 2013 | 339 | 0.020 |
Why?
|
| Splenectomy | 1 | 2012 | 166 | 0.020 |
Why?
|
| Dasatinib | 1 | 2015 | 881 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2013 | 1044 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2012 | 234 | 0.020 |
Why?
|
| Child | 1 | 2012 | 30560 | 0.020 |
Why?
|
| Nose Neoplasms | 1 | 2013 | 243 | 0.020 |
Why?
|
| Waldenstrom Macroglobulinemia | 1 | 2014 | 285 | 0.020 |
Why?
|
| RNA, Viral | 1 | 2013 | 715 | 0.020 |
Why?
|
| Sequence Deletion | 1 | 2013 | 908 | 0.020 |
Why?
|
| Time Factors | 2 | 2013 | 12978 | 0.020 |
Why?
|
| Blood Platelets | 1 | 2014 | 675 | 0.020 |
Why?
|
| Herpesvirus 4, Human | 1 | 2013 | 959 | 0.020 |
Why?
|
| Lymphoma, Follicular | 1 | 2014 | 636 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 704 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 965 | 0.020 |
Why?
|
| Translocation, Genetic | 1 | 2013 | 1286 | 0.020 |
Why?
|
| Recurrence | 1 | 2016 | 4878 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2013 | 1761 | 0.020 |
Why?
|
| Breast | 1 | 2013 | 1370 | 0.020 |
Why?
|
| Remission Induction | 1 | 2013 | 3658 | 0.020 |
Why?
|
| Genotype | 1 | 2014 | 4248 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 2560 | 0.020 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 5099 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2013 | 2157 | 0.020 |
Why?
|
| Mice | 1 | 2006 | 35421 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2013 | 4966 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2014 | 3841 | 0.010 |
Why?
|
| Treatment Outcome | 2 | 2014 | 33847 | 0.010 |
Why?
|
| Survival Rate | 1 | 2016 | 12530 | 0.010 |
Why?
|
| Tumor Microenvironment | 1 | 2013 | 3054 | 0.010 |
Why?
|
| Phenotype | 1 | 2013 | 6502 | 0.010 |
Why?
|
| Animals | 1 | 2006 | 61357 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2013 | 7232 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2012 | 9053 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 14033 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2015 | 14638 | 0.010 |
Why?
|